Asian/Asian American (A/AA) and Native Hawaiian/Pacific Islander (NH/PI) communities continue to be impacted by tuberculosis (TB) at a greater rate compared to other racial and ethnic groups. Countries with the highest TB burden among non-U.S.-born Asians and Pacific Islanders include the...
Although hepatitis B is preventable and treatable, there is still no cure for this disease. In addition to the devastating toll on patients and their families, ignoring hepatitis B costs the U.S. an estimated $4 billion per year in medical costs. Yet, the NIH will spend only $66 million in FY 2021...
The Unitaid-funded LONGEVITY project aims to develop long-acting formulations for malaria and latent tuberculosis (TB) prevention and a single-injection cure for hepatitis C virus (HCV) for low- and middle-income countries, as these diseases disproportionately affect children, poor and marginalized...
This resource walks through some of the basic elements of the Medicare program and provides information to support RWHAP Part B/ADAP staff in adapting program activities to better coordinate with Medicare coverage, including providing premium and cost-sharing assistance for clients. For a more...
The newly launched Homelessness and Infectious Disease Questions Ask a Question (AAQ) desk assists homeless assistance providers, Continuums of Care (CoCs), and other partners with questions about preventing, mitigating, and responding to infectious diseases impacting people experiencing...
The recent emergence of the Coronavirus Disease (COVID-19) calls for enhanced cooperation between public health authorities, homeless service systems, and other partners at the local level. HUD strongly encourages CoCs to contact their local public health departments, Healthcare for the Homeless...
The landscape of treatment for hepatitis C virus (HCV) infection has evolved substantially since the introduction of highly effective HCV protease inhibitor therapies in 2011. The pace of change has increased rapidly as numerous new drugs with different mechanisms of action have become available...
This document supports viral hepatitis program administrators in educating and preparing leadership to support 340B program implementation and partnerships.
This infographic discusses how girls and women make up more than half of the 37.7 million people living with HIV. Ending AIDS by 2030 requires that we address girls’ and women’s diverse roles by putting them at the centre of the response.
This graphic discusses the effects of the COVID-19 pandemic on the HIV response
